Navigation Links
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Date:12/5/2012

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Innovative CA Tumor Marker Tests Technologies and Emerging Markets

http://www.reportlinker.com/p01051205/Innovative-CA-Tumor-Marker-Tests-Technologies-and-Emerging-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

 

This report contains 278 pages, 40 tables and presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 278 pages and 40 tables

 

 

 

Table of Contents

 

I. Introduction

II. CA TUMOR MARKERS Worldwide Market and Technology Overview

A. CA Tumor Markers: Clinical Significance

and Laboratory Practices

1. CA 15-3/27.29

2. CA 19-9

3. CA 125

B. Instrumentation Review And

Market Needs

1. Abbott AxSYM

2. Abbott Architect c4000

3. Abbott Architect i2000 Series

4. Abbott Architect ci8200 System

5. Beckman Coulter UniCel Series

6. Beckman Coulter Access

7. Binding Site ESP600

8. bioMerieux Mini Vidas

9. Carolina Chemistries BioLis 24i

10. DiaSorin Liaison

11. Horiba ABX Pentra 400

12. Inverness DS2

13. J&J Vitros ECi/ECiQ

14. J&J Vitros 3600

15. J&J Vitros 5600

16. Olympus AU5400

17. Olympus AU3000i

18. Olympus AU2700

19. Roche Modular Analytics

20. Roche Cobas Integra 400

21. Roche Cobas Integra 400 Plus

22. Roche Elecsys

23. Roche Cobas c311

24. Siemens ADVIA Centaur

25. Siemens Dimension

26. Siemens Dimension RxL Max

27. Siemens Dimension Vista 500

28. Siemens Immulite

29. Siemens Stratus

30. Tosoh AIA-Series

31. Vital Diagnostics ATAC 8000

32. Vital Diagnostics Envoy 500

C. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

- Overview

- ELISA

- Immunofiltration

- Particle-Membrane Capture Immunoassay

- Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

- Chemiluminescence

- Bioluminescence

f. Latex Agglutination

g. Immunoprecipitation

H. Affinity Chromatographu

e. Liposome Flow-Injection Immunoassay

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

- PCR

- DAP-PCR

- Immuno-PCR

- QC-PCR

- CAR

- DNA

- HPA

- LCR

- NASBA

- QBR

- SDA

- 3 SR, and others

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. Two Dimensional Gel Electrophoresis (2-DGE)

8. Biosensors

9. Competing/Complementing Technologies

a. CT

b. MRI

c. NMR

d. PET

e. Photonics Spectroscopy

E. Personal Testing

III. France: Market Size, Growth and Major Suppliers'

Sales and Market Shares

IV. Germany: Market Size, Growth and Major Suppliers'

Sales and Market Shares

V. Italy: Test Volume and Diagnostics Sales Forecast

by Market Segment

VI. Japan: Market Size, Growth and Major Suppliers'

Sales and Market Shares

VII. Spain: Market Size, Growth and Major Suppliers'

Sales and Market Shares

VIII. U.K.: Test Volume and Diagnostics Sales Forecast

by Market Segment

IX. U.S.A.: Market Size, Growth and Major Suppliers'

Sales and Market Shares

XI. Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

XII. Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

XIII. Competitive Profiles

- Abbott

- AdnaGen

- Applied Gene Technologies

- Arca

- Beckman Coulter/Danaher

- Becton Dickinson

- Biomedical Diagnostics

- bioMerieux

- Bio-Rad

- Cepheid

- Correlogic Systems

- Decode

- Diadexus

- Diagnocure

- Diasorin

- Eiken Chemical

- Enterix

- Enzo Biochem

- Epigenomics

- Exact Sciences

- Fujirebio

- Gen-Probe

- Guided Therapeutics

- Hologic

- Ipsogen

- Kreatech

- Kyowa Medex

- Life Technologies

- Mackay Life Sciences

- Myriad Genetics

- Nanogen Elitech

- OncoLab

- Ortho-Clinical Diagnostics

- Panacea Pharmaceuticals

- Polartechnics

- Polymedco

- PreMD

- Qiagen

- Radient Pharmaceuticals

- Roche

- Scienion

- Sequenom

- Siemens Healthcare

- Takara Bio

- Targeted Diagnostics & Therapeutics

- Tosoh

- Veridex

- Wako Pure Chemicals

- Wallac/PE

- Zila

 

List of Tables

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

France

CA 15-3/27.29 Test Volume and Diagnostics Sales

by Market Segment

France

CA 19-9 Test Volume and Diagnostics Sales

by Market Segment

France

CA 125 Test Volume and Diagnostics Sales

by Market Segment

France

CA 15-3/27.29 Testing Market by Major Supplier

France

CA 19-9 Testing Market by Major Supplier

France

CA 125 Testing Market by Major Supplier

Germany

CA 15-3/27.29 Test Volume and Diagnostics Sales

by Market Segment

Germany

CA 19-9 Test Volume and Diagnostics Sales

by Market Segment

Germany

CA 125 Test Volume and Diagnostics Sales

by Market Segment

Germany

CA 15-3/27.29 Testing Market by Major Supplier

Germany

CA 19-9 Testing Market by Major Supplier

Germany

CA 125 Testing Market by Major Supplier

Italy

CA 15-3/27.29 Test Volume and Diagnostics Sales

by Market Segment

Italy

CA 19-9 Test Volume and Diagnostics Sales

by Market Segment

Italy

CA 125 Test Volume and Diagnostics Sales

by Market Segment

Japan

CA 15-3/27.29 Test Volume and Diagnostics Sales

by Market Segment

Japan

CA 19-9 Test Volume and Diagnostics Sales

by Market Segment

Japan

CA 125 Test Volume and Diagnostics Sales

by Market Segment

Japan

CA 15-3/27.29 Testing Market by Major Supplier

Japan

CA 19-9 Testing Market by Major Supplier

Japan

CA 125 Testing Market by Major Supplier

Spain

CA 15-3/27.29 Test Volume and Diagnostics Sales

by Market Segment

Spain

CA 19-9 Test Volume and Diagnostics Sales

by Market Segment

Spain

CA 125 Test Volume and Diagnostics Sales

by Market Segment

Spain

CA 15-3/27.29 Testing Market by Major Supplier

Spain

CA 19-9 Testing Market by Major Supplier

Spain

CA 125 Testing Market by Major Supplier

U.K.

CA 15-3/27.29 Test Volume and Diagnostics Sales

by Market Segment

U.K.

CA 19-9 Test Volume and Diagnostics Sales

by Market Segment

U.K.

CA 125 Test Volume and Diagnostics Sales

by Market Segment

U.S.A.

CA 15-3/27.29 Test Volume and Diagnostics Sales

by Market Segment

U.S.A.

CA 19-9 Test Volume and Diagnostics Sales

by Market Segment

U.S.A.

CA 125 Test Volume and Diagnostics Sales

by Market Segment

U.S.A.

CA 15-3/27.29 Testing Market by Major Supplier

U.S.A.

CA 19-9 Testing Market by Major Supplier

U.S.A.

CA 125 Testing Market by Major Supplier

 

 

 

To order this report:

In_Vitro_Diagnostic Industry: Innovative CA Tumor Marker Tests Technologies and Emerging Markets

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ClinicalKey Key Innovator Award to Recognize the Innovative Use of Health Information and Technology to Save and Improve Lives
2. Andain Inc. the Innovative Technology Incubator, Receives DTC Eligibility
3. Sihuan Pharmaceutical Collaborates with NeuroVive to Develop Two Innovative Cardio-cerebral Vascular Products in China
4. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
5. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
6. Frost & Sullivan: Respirator Manufacturers to Develop Innovative Solutions to Overcome Economic Challenges in North America
7. Innovative Drugs to Transform European Alzheimers Disease Medication Market by 2015, Says Frost & Sullivan
8. Coloplast Launches the Innovative Altis Single Incision Sling System
9. DebMed Selected By Three Leading Healthcare Group Purchasing Organizations To Demonstrate Innovative Patient Safety Solution
10. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
11. Tranzbyte Corporation Acquires the Exclusive Right to Market Low-Cost, Innovative MRI machines in North and South America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):